ONCYTE

OnCyte offers autologous CAR T-Cell drug candidate CM-CS1. CM-CS1 is an autologous CAR T-cell therapy which employs NKG2D, a “natural killer” cell receptor designed to target ligands present on most tumor types, including hematologic cancers as well as solid tumors. OnCyte’s portfolio also includes an allogeneic T-Cell platform designed to enable almost any CAR T-Cell therapy to be made into an “off-the-shelf” product. The platform is based on the engineering of T cells from healthy d... onors that, in addition to CAR, also express TCR Inhibitory Molecules. These molecules inhibit TCR function allowing the T cells to persist when injected into a patient. OnCyte’s CAR T-Cell technology is based on research by Charles L. Sentman, Ph.D., director of the Center for Synthetic Immunity and a professor of microbiology and immunity at Geisel School of Medicine at Dartmouth.More